PCM
BDTX icon

Prelude Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Prelude Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,895
Closed -$29.6K – 1256
2026
Q1 		$29.6K Buy
+13,895
New +$33K ﹤0.01% 1151
2022
Q4 		– Sell
-10,541
Closed -$18K – 1334
2022
Q3 		$18K Buy
+10,541
New +$32.5K ﹤0.01% 1279
2022
Q1 		– Sell
-11,483
Closed -$61K – 1830
2021
Q4 		$61K Buy
+11,483
New +$80.2K ﹤0.01% 1767

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Prelude Capital Management's BDTX Position: Q2 2026 in Review

Prelude Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 13,895 shares — an estimated $29.6K sold.

Prelude Capital Management first reported a position in BDTX in Q4 2021 and held it in 3 quarters. The position peaked at $61K in Q4 2021. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Prelude Capital Management reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 13,895 Black Diamond Therapeutics shares in Q2 2026, an estimated $29.6K.
  • Prelude Capital Management first reported a position in Black Diamond Therapeutics in Q4 2021 and held it in 3 quarters.
  • Prelude Capital Management's Black Diamond Therapeutics position peaked at $61K in Q4 2021.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.